Eugean Jiwanmall, MPH, MBA

home / authors / eugean-jiwanmall-mph-mba

Articles

March 11th 2022

Comprehensive Genomic Profiling in Community Oncology

Bruce Feinberg, DO Kenna R. Mills Shaw, PhD Mark G. Kris, MD Eugean Jiwanmall, MPH, MBA

Recommendations to address limitations in more widespread use of reflex testing in community oncology.

March 11th 2022

Future Outlook: Coverage for Comprehensive Genomic Profiling in Oncology

Bruce Feinberg, DO Eugean Jiwanmall, MPH, MBA Mark G. Kris, MD

How payers will support the use of comprehensive genomic profiling in oncology moving forward.

March 11th 2022

Future Outlook: Comprehensive Genomic Profiling in Oncology

Bruce Feinberg, DO Mark G. Kris, MD Kenna R. Mills Shaw, PhD Eugean Jiwanmall, MPH, MBA

Expectations regarding the future utilization of comprehensive genomic profiling in clinical practice to assess patients with solid tumor cancers.

March 4th 2022

Reflex Testing and Reimbursements for Oncology Treatment

Bruce Feinberg, DO Eugean Jiwanmall, MPH, MBA

Payer perspective regarding decisions for covering the costs of molecular assays in oncology and reimbursing oncologists for treatments provided to patients while navigating long turnaround times associated with reflex testing.

February 25th 2022

Comprehensive Genomic Profiling and Procedure Coding

Bruce Feinberg, DO Eugean Jiwanmall, MPH, MBA

Criteria used by payers to determine how to code and support the use of various genomic profiling assays used in oncology.

February 18th 2022

Comprehensive Genomic Profiling and Clinical Actionability

Bruce Feinberg, DO Eugean Jiwanmall, MPH, MBA Kenna R. Mills Shaw, PhD

Payer response to supporting decisions for coverage of comprehensive genomic profiling in oncology.

February 11th 2022

Shifting Over to Comprehensive Genomic Profiling in Oncology

Bruce Feinberg, DO Mark G. Kris, MD Kenna R. Mills Shaw, PhD Eugean Jiwanmall, MPH, MBA

The rationale for migrating away from single, spot testing to comprehensive genomic profiling assays in oncology.

February 3rd 2022

Types of Molecular Assays Used in Oncology

Bruce Feinberg, DO Kenna R. Mills Shaw, PhD Eugean Jiwanmall, MPH, MBA

Oncologists who manage patients with solid tumors compare and contrast current comprehensive molecular assays being used in clinical practice and discuss reimbursement criteria with payer, Eugean Jiwanmall, MPH, MBA.

January 28th 2022

Molecular Profiling Complexities and Coverage Decisions

Eugean Jiwanmall, MPH, MBA Bruce Feinberg, DO Mark G. Kris, MD

Considerations regarding coverage decisions to support the large amount of information provided by molecular testing assays and the validity of results in terms of clinical decision-making.